Ticagrelor Tablet, Film Coated
Product Images NDC 0480-2695

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 0480-2695). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New1 (Image 1)

This is a comparison study between two drugs, Tigomg and Clopidogrel, for patients with events over a 12-month period. The study shows the percentage of patients with events, KM % at 12 months, and the days from the first dose of the study drug. Tigomg had 362 events (3.9%) compared to Clopidogrel with 306 events (3.3%) at 12 months. The progression of events over time is shown in the table.*

FDA Label Image

New9 (Image 10)

This text provides information on the interaction between Ticagrelor and various drugs. It includes the mean effect and 90% confidence intervals for different drug combinations involving Ticagrelor doses. Recommendations include details on dose adjustments and monitoring for drugs like Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. Additionally, it mentions the need to monitor digoxin levels when initiating or changing Ticagrelor therapy.*

FDA Label Image

New10 (Image 11)

Not available.*

FDA Label Image

New11 (Image 12)

This is a clinical trial dataset showing characteristics of patients involved in the study such as geographic region distribution, ASA dosage, treatment approaches, medical history (diabetes, prior stroke), age distribution, gender, race, and comparison of efficacy between two medications - Ticagrelor and Clopidogrel. The data includes percentages, values, and hazard ratios with confidence intervals for different parameters. The study evaluates the overall treatment effect and endpoints based on various factors.*

FDA Label Image

New12 (Image 13)

This text seems to be related to a study or analysis comparing the dose and outcomes of Ticagrelor versus Clopidogrel. The data includes information such as the region, dose ranges, number of participants, events, Hazard Ratios (HR), and Confidence Intervals (CI). The study includes participants from both the US and non-US regions. The HR values from the study suggest the relative effectiveness of Ticagrelor compared to Clopidogrel across different dose categories. Additionally, the text mentions Ticagrelor and Clopidogrel as the subjects of comparison.*

FDA Label Image

New13 (Image 14)

The text provides numerical data related to a study involving patients and different treatments, including Tioomg and Placebo. It includes information about the number of patients with events, Kaplan-Meier estimates at 36 months, hazard ratios (with confidence intervals), and days from randomization. The data seems to be related to a clinical trial or research study evaluating the effectiveness of the treatments.*

FDA Label Image

New14 (Image 15)

This is a comprehensive table showing the treatment effect of Ticagrelor compared to placebo in different subgroups based on characteristics such as age group, sex, race, weight group, diabetes status, smoking status, history of PCI, type of stent, and timing of previous ADP receptor blocker treatment. The data includes the number of participants, hazard ratios (with 95% confidence intervals), and percentage of participants in each subgroup. The comparison indicates whether Ticagrelor was better or worse than placebo in terms of treatment effect within each subgroup.*

FDA Label Image

New15 (Image 16)

This data represents the cumulative percentage of patients experiencing a Natrisk event over time in a study comparing Ticagrelor and Placebo. The study tracked patients for up to 54 months from randomization, with the number of patients in each group indicated as T (Ticagrelor) and P (Placebo). The results show the percentage of patients experiencing Natrisk events at different time points during the study.*

FDA Label Image

New16 (Image 17)

Characteristic HR (95% CI): This section provides hazard ratios and their 95% confidence intervals comparing Ticagrelor to Placebo among different subsets of patients based on various characteristics such as age, race, body mass index, renal function, history of cardiovascular procedures (PCI, CABG), smoking status, duration of diabetes, and others. The hazard ratios indicate the likelihood of certain events occurring in the Ticagrelor group compared to the Placebo group within the specified characteristics. These ratios help in understanding the effectiveness or risk associated with Ticagrelor treatment across different patient groups.*

FDA Label Image

New17 (Image 18)

This is a comparison of Ticagrelor (90 mg) and Placebo in a study regarding events. The data includes the number of events over time, cumulative percentages, and days from randomization. Ticagrelor had a lower percentage of events compared to Placebo. The chart displays the cumulative percentages over 34 days.*

FDA Label Image

New18 (Image 19)

The text provides detailed information on patient characteristics, including age distribution, BMI, geographic region, diagnoses, medical history, and treatment status, in a clinical trial setting. It also includes data on the outcomes comparing Ticagrelor and Placebo in percentages. Additionally, it presents hazard ratios with 95% confidence intervals for various comparisons in the study. This information can be used for further analysis and interpretation of the effectiveness of Ticagrelor in different patient subgroups.*

FDA Label Image

New2 (Image 2)

FDA Label Image

New (Image 20)

This text is a medication label providing information about Ticagrelor tablets. It includes details such as dosage instructions, storage conditions, and manufacturing information. The tablets should be stored at 25°C with excursions permitted to 15°-30°C. Pharmacists are advised to dispense the medication with caution, in tight containers. Additionally, the text mentions printing Medication Guides from the website www.tevausa.com/medguides. The medication is manufactured in India for Teva Pharmaceuticals, and each film-coated tablet contains Ticagrelor.*

FDA Label Image

New (Image 21)

This text contains information related to medication guide for TICAGRELOR DIOMAION PO 0480-2695-06 tablets. It includes details on proper storage conditions, precautions, and manufacturing information. The medication is manufactured in India by Watson Pharma Private Limited and is distributed by Teva Pharmaceuticals. It is advised to keep this medication out of the reach of children.*

FDA Label Image

New3 (Image 3)

This is a data table showing the results of a study comparing Ticagrelor with a placebo in a group of patients over different time points. The table includes the cumulative percentage of patients in each group at various time intervals from randomization. It also indicates the number of patients in each group (Ticagrelor and Placebo) at different time points. The study aims to evaluate the effectiveness of Ticagrelor compared to a placebo in the treatment of a certain condition.*

FDA Label Image

New4 (Image 4)

This is a description of a clinical trial comparing Ticagrelor (90mg bd) to Placebo. The text includes data on the number of events, percentage, days from randomization, and number at risk for each treatment group. The study shows the outcomes over a period of 34 days.*

FDA Label Image

Chemical Structure (Image 5)

FDA Label Image

New5 (Image 6)

FDA Label Image

New6 (Image 7)

FDA Label Image

New7 (Image 8)

FDA Label Image

New8 (Image 9)

The text contains information on drug interactions with Ticagrelor ARC124910XX and recommendations based on CYP3A4 enzyme activity. It includes details on the interactions with various inhibitors and inducers and provides specific dosage adjustments. The text also mentions limitations on dose adjustments and references for further information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.